Key Figures on **Biosimilars**

GBMA
Generic and Biosimilar Medicines Association

BIOSIMILARS IN EUROPE

10 YEARS

10 YEARS EUROPEAN EXPERIENCE

FIRST BIOSIMILAR
APPROVED IN EUROPE 2006

+400M
PATIENT DAYS

OVER 400 MILLION
PATIENT DAYS IN EUROPE[1]

GLOBAL SAVINGS

€100B

GLOBAL SAVINGS FROM BIOSIMILARS
EXPECTED TO BE €100B BY 2020[1]

BIOSIMILARS IN AUSTRALIA

FIRST BIOSIMILAR
IN AUSTRALIA IN 2011

INFLIXIMAB: FIRST BIOSIMILAR
MONOCLONAL ANTIBODY (mAb)
IN AUSTRALIA IN 2015

BIOSIMILAR FILGRASTIM
+30% PATIENT ACCESS, -13% COST
(2011-2014)[2]

$2.6B

POTENTIAL MARKET FOR BIOSIMILARS
$2.6B PER YEAR[2]

OUTCOMES

IMPROVED PATIENT ACCESS TO LIFE CHANGING MEDICINES
MORE PATIENTS TREATED FOR THE SAME COST

PBS SAVINGS THROUGH
COMPETITION AND PRICE DISCLOSURE

MORE $ AVAILABLE FOR THE PBS
TO SPEND ON NEW MEDICINES

1. IMS Institute Report March 2016 **2.** IMS Data

Making medicines affordable